Selank
Medium EvidenceA synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties.
What It Is
Selank is a heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a synthetic analog of the immunomodulatory peptide tuftsin, with an added Pro-Gly-Pro sequence for stability. It has been studied for anxiolytic, nootropic, and immunomodulatory effects. In 2026, laboratory programs are examining how Selank interacts at the receptor level within the BDNF-TrkB and GABAergic signaling systems, with improved analytical instrumentation making preclinical research more precise and reproducible. Advances in nasal and transdermal delivery mechanisms have also improved bioavailability studies. Selank is commonly studied alongside Semax in cognitive peptide research stacks. It is registered as an anxiolytic in Russia but has no FDA approval and is not currently scheduled for PCAC review in the July 2026 sessions.
Regulatory Status
Returned to Category 1 compounding eligibility under FDA's February 2026 reclassification. May be compounded by 503A/503B pharmacies under physician prescription.
Effective: February 2026
View FDA SourceEvidence Snapshot
Commonly Discussed Benefits
Safety & Cautions
- Approved in Russia but not FDA-approved in the US
- Most research published in Russian-language journals
- Long-term Western clinical data limited
- Discuss with a healthcare provider
Comparisons
See how Selank compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
Continue Your Research
Track your research notes and set reminders in the companion app.
Related Peptides
Semax
Medium EvidenceA synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects.
DSIP
Low EvidenceA neuropeptide studied for its role in sleep regulation and stress modulation.
P21
Medium EvidenceAn 11-amino-acid CNTF-derived peptide studied for its ability to upregulate BDNF expression and promote neurogenesis in cognitive decline models.